Abstract
The in vitro activity of telavancin was tested against 620 gram-positive isolates. For staphylococci, MICs at which 50 and 90% of isolates were inhibited (MIC(50) and MIC(90)) were both 0.25 microg/ml, irrespective of methicillin resistance. MIC(50) and MIC(90) were 0.25 and 0.5 microg/ml for vancomycin-susceptible enterococci and 1 and 2 microg/ml for vancomycin-resistant enterococci, respectively. Streptococcus pneumoniae, group A and B beta-hemolytic streptococci, and viridans streptococci were inhibited by < or =0.12 microg/ml.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aminoglycosides / pharmacology*
-
Anti-Bacterial Agents / pharmacology*
-
Drug Resistance, Multiple, Bacterial
-
Europe
-
Gram-Positive Bacteria / drug effects*
-
Gram-Positive Bacterial Infections / microbiology*
-
Humans
-
Lipoglycopeptides
-
Methicillin Resistance
-
Microbial Sensitivity Tests
-
Staphylococcus aureus / drug effects
-
Streptococcus agalactiae / drug effects
-
Streptococcus pyogenes / drug effects
-
Vancomycin Resistance
-
Viridans Streptococci / drug effects
Substances
-
Aminoglycosides
-
Anti-Bacterial Agents
-
Lipoglycopeptides
-
telavancin